Short answer
Absci Corp (ABSI) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events), Item EX-99.2 (Exhibit EX-99.2), Item EX-99.1 (Exhibit EX-99.1). Third-quarter fiscal 2026 results announced for period ended September 30, 2026.
Absci Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Third-quarter fiscal 2026 results announced for period ended September 30, 2026
- Full financial results and management commentary available in Exhibit 99.1
- Release provides investors the quarter’s latest operating and financial update
Item 8.01 · Other Events
- Absci released an investor presentation on November 12, 2026 covering internal pipeline program updates
- Pipeline disclosures may affect investor views on development priorities, clinical progress and future catalysts
- Full program details are in Exhibit 99.2 and the company’s News & Events webpage
Item EX-99.1 · Exhibit EX-99.1
- ABS-201 HEADLINE trial on track, with 13-week pattern hair-loss proof-of-concept data expected December 2026 and full 26-week data early 2027
- Planned Phase 2 STORYLINE endometriosis trial targets approximately 150 patients across approximately 10 countries, with initiation anticipated mid-2027
- Q3 revenue $0.3M versus $0.4M, while R&D rose to $23.6M from $19.2M, reflecting heavier ABS-201 development investment
- Net loss widened to $33.3M from $28.7M, with loss per share improving to $(0.19) from $(0.20) on higher share count
- Cash, equivalents and marketable securities $173.7M at September 30, 2026, expected to fund operations into the second half of 2028
Item EX-99.2 · Exhibit EX-99.2
- Corporate presentation highlights ABS-201’s Ph1/2a PHL program, with interim proof-of-concept readout expected December 2026
- Interim SAD data showed favorable blinded safety and tolerability, with half-life of at least 65 days
- ABS-201 targets an estimated 80M U.S. PHL patients and a potential global market exceeding $40B, based on company-commissioned research
- Endometriosis expansion targets roughly 9M U.S. patients, with Phase 2 initiation expected mid-2027 and potential peak sales above $4.5B
- Pipeline includes ABS-101 for IBD and multiple partnering-ready programs, supporting potential non-ABS-201 collaboration catalysts
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Absci Corp 8-K filings
Get the next ABSI 8-K as it lands
Follow ABSI for push alerts, or ask the research agent what this filing means.